Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Core Insights - Voyager Therapeutics is focusing on three key pillars of value for the upcoming year, with a significant emphasis on the tau target and gene therapy initiatives [2]. Group 1: Company Overview - Voyager Therapeutics has outlined an important year ahead, highlighting its strategic focus on the tau target with two specific therapeutic approaches [2]. - The company plans to advance two different gene therapy assets into clinical trials, leveraging its innovative blood-brain barrier penetrant capsids [3].